about
SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131ITissue-specific promoters active in CD44+CD24-/low breast cancer cellsOncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29.Validity and reliability of the Fatigue Severity Scale in Finnish multiple sclerosis patientsGeneration of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue.Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells.Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity.Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.Type I interferon response against viral and non-viral gene transfer in human tumor and primary cell lines.Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.Utility of cell-permeable peptides for enhancement of virus-mediated gene transfer to human tumor cells.hCAR-EGFP fusion receptor in human follicular lymphoma B cells - a model for adenoviral gene therapy for B cell malignancies.Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.HIV-1 TAT protein transduction domain mediates enhancement of enzyme prodrug cancer gene therapy in vitro: a study with TAT-TK-GFP triple fusion construct.VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.TK-GFP fusion gene virus vectors as tools for studying the features of HSV-TK/ganciclovir cancer gene therapy in vivo.Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNISThe secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy.Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.In vivo enhancement of herpes simplex virus thymidine kinase/ganciclovir cancer gene therapy with polyamine biosynthesis inhibition.Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential.Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses.[Adenoviruses in cancer therapy]
P50
Q27307734-AE9D9186-3E90-4456-858D-7BC300D6A5F0Q28287391-1B0C75F6-0CC3-4C38-8A4E-3DDC774A73D7Q33298585-6AC35D83-5614-4EBE-AD07-09F3B0C37913Q33917369-7761016F-A86C-41FA-B932-190727030CC0Q33917437-D4BEE39E-7D26-48CD-ADD9-9AF8E6C9318CQ34830129-5A70662F-FAB7-4D0E-95C6-4386BCD1CFD6Q35285768-F8930896-C622-4A61-BA05-244FB3B1B94FQ36971659-4A09F815-D7E1-4265-BE7F-CA01A38F3F2EQ38351472-5E6A1DB3-DBF6-48B6-9BA4-9C217CC16853Q39524013-6A503340-5CF7-4972-B16D-E96EA4093ACEQ39715174-EF5E44C6-98FA-4A3D-A459-7A76474E9E1DQ39808222-F813FB5C-D9FE-4127-AE1A-8C68BC7003ABQ39929003-53A6276A-3B11-45D3-85A7-348E66B86E2DQ40002810-016DF68D-EA44-4677-9516-0CCF66D292E8Q40168283-698CC458-28C5-4D88-B52A-33ACD9A75F39Q40190008-067065E8-66D8-4292-BB7A-E0A0051CD16DQ40224518-BE9C08BC-C5E0-44CE-BDAD-67D2DE0D3C96Q40278361-9A02D17E-7A1B-4E94-B8A5-4A5C6A063BFCQ40281862-A3BF2A94-53A4-47FD-A5C4-39C8AFA07893Q40297448-11E90E47-CF14-4C63-8E58-A9F380E9D74CQ40412517-ED91E2DF-225B-45FB-A1BC-88998D352C9CQ40448228-DA6F011D-748C-46E9-8963-C36C16814A32Q40636061-0BC6355D-47A8-450B-9A51-C33C8C3ADE6EQ42709652-CAB5D63A-E86C-4562-9866-B9ADF0C36FA0Q44401684-6A3C039F-AE75-4FEC-8C07-E41FA81F49A7Q45152963-08235B33-15F0-4DCD-8738-0E3D8084A6FDQ45407078-628171A4-C916-44A9-B5A7-85F06D5A05A7Q45421226-9D83E012-EF85-483A-A47A-5B749AF4090AQ45863944-27894B84-819F-4BCE-B97C-5E3F30DC3585Q45865081-017AFACC-B723-48D6-B0CF-1CE0D38C8ADCQ45869203-A0F85518-182A-43A8-A490-919451E6B9F8Q45871953-B06ACEE7-FB9D-4AFE-8CFE-9E8E0E85B598Q50091640-E2438F66-6BFE-4283-89A9-64F9E0CCE117Q50103083-D5176350-F851-464A-83B8-7BF8CAEAD952Q64378062-7BC3C18F-C708-4F2B-8466-873FA21C3B32
P50
name
Tanja Hakkarainen
@ast
Tanja Hakkarainen
@en
Tanja Hakkarainen
@nl
type
label
Tanja Hakkarainen
@ast
Tanja Hakkarainen
@en
Tanja Hakkarainen
@nl
prefLabel
Tanja Hakkarainen
@ast
Tanja Hakkarainen
@en
Tanja Hakkarainen
@nl